伊立替康治疗复发性晚期卵巢癌

目的：观察国产伊立替康单药治疗复发性晚期卵巢癌的近期疗效和不良反应。方法：对晚期卵巢癌患者采用伊立替康单药化疗。入组患者均经病理组织学证实,且有可测量病灶。结果：在可评价的30例的患者中,CR 10.0%,PR 23.3%,SD 30.0%,PD 30.0%,总缓解率33.3%,中位疾病进展期6.8个月,中位生存期12.7个月,主要不良反应为迟发性腹泻和中性粒细胞减少,未出现治疗相关性死亡。结论：伊立替康治疗晚期卵巢癌有较好疗效,毒副反应可以耐受。     

DC方案同期放化疗治疗局部晚期鼻咽癌疗效观察

将92例Ⅲ、Ⅳa期初治鼻咽癌患者随机分为治疗组(同期化放疗组)和对照组(单纯放疗组).化疗方案采用DC方案(多西他赛 顺铂),放疗采用6MV X线常规分割.结果 治疗组总有效率为95.3%,两组总有效率、无复发生存率无统计学差异(P＞0.05);总生存率和无远处转移率有统计学差异(P＜0.05).观察组不良反应较对照组严重,但经积极处理均可耐受.认为DC方案与放疗同步治疗局部晚期鼻咽癌可获得较理想的无复发生存率和总生存率.     

塞来昔布对人鼻咽癌CNE-2细胞生长抑制及放射增敏研究

Objective To investigate the growth inhibition and radiosensitization of Celecoxib in hu-man nasopharyngeal carcinoma cell line CNE-2. Methods CNE-2 growth inhibition by Celecoxib was eval-uated by MTT method. Apoptosis-related changes in morphology were observed by transmission electron mi-croscopy (TEM). Cell cycle distribution and apoptosis rate were measured by flowcytometry (FCM). The ex-pression of COX-2 protein was observed by SP method after the treatment of Celecoxib. Cells were randomly planted into four groups: irradiation control(Ci), drug group(Cd), irradiation group(R), and Celecoxib plus irradiation group(D+R). Single irradiation of 2,4,6,8,and 10 Gy were administered for colonogenic assay. Cell cycle distribution and apoptosis rate were analyzed at 6 Gy irradiation. Results The growth of CNE-2 cell was inhibited by celecoxib in a dose-and time-dependent manner, the IC50 was 80 μmol/L After the treatment, cell ratio of GO and G, phases was increased (47.03±2.76 vs 56.17±1.95, t=4.68, P= 0.010), whereas the ratio of S and G2/M phases was decreased (33.07±1.86 vs 24.87±1.76, t=5.54, P = 0.010; 19.30±0.53: 17.73±0.83, t=2.75, P=0.050), and the apoptosis rate was increased (1.57±0.47:10.47±0.31, t = 27.39, P = 0.000) in a dose-dependent manner. Apoptosis with nuclear chromatin condensation, fragmentation and cell shrinkage was found by TEM. SP method showed that Celeib decreased COX-2 expression (17.48±0.34 vs 12.82±0.51,t=13.20,P =0.00). The sensitivity ratio(D0) was 1.15. FCM showed that the percentage of cells in G2/M phase was significanty more in R and D+R groups than in Ci and Cd groups (68.00±1.65,54.27±5.74,17.60±0.80,14.86±1.23, t=47.70,P=0.000; t=11.63, P=0.000), and also significantly different between R group and D + R group (t=3.99, P= 0.020). The apoptosis rate was higher in R and D + R groups than Ci and Cd groups(4.83±0.97,9.50± 1.35,1.33±0.86 and 2.28±0.42,t=4.67,P=0.010;t=8.81, P=0.000), D + R group than R group(t =4.85,P=0.010). Conclusions Celecoxib can markedly inhibit the growth and induce apoptosis in CNE-2 cells,which may depend on COX-2 pathway. Celeeoxib potently enhances the radiosensitivity of CNE-2 cells,which may due to the repair inhibit of radiation-induced DNA damage, inhibit of cell proliferation,and enhancement of cell apoptosis after irradiation.     

重组IL-11治疗化疗后所致血小板低下的临床观察

目的 观察重组人白介素-11对化疗后所致血小板低下的治疗作用和不良反应.方法 化疗后血小板低于50×109/L的恶性肿瘤患者42例,随机分为两组,治疗组用IL-11 25 μg/(kg·d)皮下注射,连用7 d;对照组皮下注射生理盐水,以用药1周和14 d后外周血血小板的值进行对照.结果 用药1周后治疗组与对照组血小板的均值分别为(91.26±21.54)×109/L和(70.34±19.72)×109/L,14 d后血小板的均值分别为(145.67±88.92)×109/L和(87.39±13.56)×109/L,两者间差异有显著性(P＜0.05).治疗组血小板＞100×109/L者16例(76.2%),对照组3例(14.3%,P＜0.01).治疗组1例患者输注血小板,对照组3例患者输注血小板.主要不良反应为关节肌肉酸痛、乏力、水肿等,其他不良反应少见.结论 重组人白细胞介素-11可治疗化疗后血小板低下,缩短血小板下降的持续时间,减少血小板的输注次数,而且不良反应可以耐受,值得临床进一步观察.     

塞来昔布对人鼻咽癌CNE-2细胞生长抑制及放射增敏研究

Objective To investigate the growth inhibition and radiosensitization of Celecoxib in hu-man nasopharyngeal carcinoma cell line CNE-2. Methods CNE-2 growth inhibition by Celecoxib was eval-uated by MTT method. Apoptosis-related changes in morphology were observed by transmission electron mi-croscopy (TEM). Cell cycle distribution and apoptosis rate were measured by flowcytometry (FCM). The ex-pression of COX-2 protein was observed by SP method after the treatment of Celecoxib. Cells were randomly planted into four groups: irradiation control(Ci), drug group(Cd), irradiation group(R), and Celecoxib plus irradiation group(D+R). Single irradiation of 2,4,6,8,and 10 Gy were administered for colonogenic assay. Cell cycle distribution and apoptosis rate were analyzed at 6 Gy irradiation. Results The growth of CNE-2 cell was inhibited by celecoxib in a dose-and time-dependent manner, the IC50 was 80 μmol/L After the treatment, cell ratio of GO and G, phases was increased (47.03±2.76 vs 56.17±1.95, t=4.68, P= 0.010), whereas the ratio of S and G2/M phases was decreased (33.07±1.86 vs 24.87±1.76, t=5.54, P = 0.010; 19.30±0.53: 17.73±0.83, t=2.75, P=0.050), and the apoptosis rate was increased (1.57±0.47:10.47±0.31, t = 27.39, P = 0.000) in a dose-dependent manner. Apoptosis with nuclear chromatin condensation, fragmentation and cell shrinkage was found by TEM. SP method showed that Celeib decreased COX-2 expression (17.48±0.34 vs 12.82±0.51,t=13.20,P =0.00). The sensitivity ratio(D0) was 1.15. FCM showed that the percentage of cells in G2/M phase was significanty more in R and D+R groups than in Ci and Cd groups (68.00±1.65,54.27±5.74,17.60±0.80,14.86±1.23, t=47.70,P=0.000; t=11.63, P=0.000), and also significantly different between R group and D + R group (t=3.99, P= 0.020). The apoptosis rate was higher in R and D + R groups than Ci and Cd groups(4.83±0.97,9.50± 1.35,1.33±0.86 and 2.28±0.42,t=4.67,P=0.010;t=8.81, P=0.000), D + R group than R group(t =4.85,P=0.010). Conclusions Celecoxib can markedly inhibit the growth and induce apoptosis in CNE-2 cells,which may depend on COX-2 pathway. Celeeoxib potently enhances the radiosensitivity of CNE-2 cells,which may due to the repair inhibit of radiation-induced DNA damage, inhibit of cell proliferation,and enhancement of cell apoptosis after irradiation.     

病毒性心肌炎120例12年随访观察

病毒性心肌炎１２０例１２年随访观察宋金钟，吕世勤，胡玉兰，许新华为了观察病毒性心肌炎自急性期以后不同时期的痊愈率，我们对１９８０～１９８７年以来收治的１２０例病毒性心肌炎进行了长期随访，现将结果报告如下。１对象与方法本组１２０例均符合１９８７年全国心...     

DHAP方案治疗复发难治性非霍奇金淋巴瘤的临床疗效观察

为了观察DHAP方案治疗复发难治性非霍奇金淋巴瘤(non Hodgkin’slymphoma,NHL)的临床疗效和不良反应,选择复发难治性NHL患者34例,采用DHAP方案化疗:DDP100mg/m2,静脉滴入3h,d1;Ara C2g/m2,静脉滴入3h,d2,每12h1次;DXM40mg/d,口服或静脉推注,d1～d4。21～28d为1周期,共完成1～6个周期,中位周期数为3.5。34例患者CR11例(32.4%),PR6例(17.6%),SD13例(38.2%),PD4例(11.8%),总有效率为50%(17/34)。主要毒副反应为血细胞下降和消化道反应,其白细胞Ⅲ～Ⅳ度下降发生率为52.9%(18/34),血小板Ⅲ～Ⅳ度下降发生率为73.5%(25/34),Ⅰ～Ⅱ度消化道反应为14.7%(5/34),其他不良反应少见。初步研究结果显示,DHAP方案是治疗复发难治性NHL的有效解救化疗方案,缓解率高,不良反应可以耐受,值得临床进一步观察。     

高强度聚焦超声治疗子宫肌瘤18例的疗效观察

目的：探讨高强度聚焦超声（high intensity focused ultrasound，HIFU）治疗子宫肌瘤的有效性和安全性。方法：选择我院确诊的18例子宫肌瘤患者，通过HIFU治疗后观察比较治疗前后肌瘤回声、大小、血流及临床症状的改变。结果：子宫肌瘤内部回声增强，瘤体缩小，临床症状改善，无严重副作用。结论：HI-Fu治疗子宫肌瘤安全、有效，值得进一步研究、观察。